Jim Hindman

Aatru Medical, LLC (Aatru) is a privately-held medical device company specializing in negative pressure wound therapy (NPWT) for surgical incisions. The Aatru NPSIMS™ is the first new technology development for NPWT in 10 years, wtih a unique, safe, and cost effective ultraportable device that is designed for use on closed surgical incisions that produce low exudate. The NPSIMS™ product has received 510(k) FDA Clearance and has launched commercial sales in Latin America and the US. Visit the Aatru website for more information.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).

Aatru Medical, LLC (Aatru) is a privately-held medical device company specializing in negative pressure wound therapy (NPWT) for surgical incisions. The Aatru NPSIMS™ is the first new technology development for NPWT in 10 years, wtih a unique, safe, and cost effective ultraportable device that is designed for use on closed surgical incisions that produce low exudate. The NPSIMS™ product has received 510(k) FDA Clearance and has launched commercial sales in Latin America and the US. Visit the Aatru website for more information.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).